OriginalArticle ClinicalFeaturesandTreatmentOutcomeofPatientswith

Objective: To study the clinical manifestations and treatment outcome of patients with non-Hodgkin lymphoma (NHL) treated at Sawanpracharak Hospital. Materials and Methods: A retrospective analysis of 113 patients with newly diagnosed NHL treated from January 2005 to December 2009 was performed. Results: The mean age was 56.3 ± 13.6 years (range, 20-86), male:female ratio was 1:1.1. The most common histologic subtype was diffuse large cell lymphoma (66.4%), followed by follicular lymphoma (5.3%), and peripheral T-cell lymphoma (4.4%). Immunophenotypic data showed 89.2 % of B cell and 9.9 % of T cell lymphoma. Three patients (2.7%) had HIV infection. According to the International Prognostic Index (IPI), distribution of 91 patients with aggressive lymphoma were 29.6%, 22.0%, 25.3%, and 23.1 % in low, low intermediate, high intermediate and high risk groups, respectively. Primary extranodal lymphomas comprised 36.3 % of all patients and the most common site was gastrointestinal tract (39.0%). Most of the patients (77.9%) were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone). Of the 98 evaluable patients, 52.0 % achieved complete remission and 19.4 % died during treatment. The 3-year overall survival rate was 37.6 % (95%CI: 27.7-47.4) with a median followed-up time of 1.4 years (range, 26 days-6.7 years). According to IPI, the 3-year survival rate was signifi-cantly better in low/low intermediate risk group than in high intermediate/high risk group, (61.3 % vs.15.3%, p < 0.001). Conclusion: Patients with NHL in the present study were comparable to published Thai data. Th